Tumour cells surviving in vivo cisplatin chemotherapy display elevated c-myc expression

British Journal of Cancer

Volumn 73, Issue 5, 1996, Pages 610-614

  Walker, T L ^a   White, J D ^a   Esdale, W J ^a   Burton, M A ^a   DeCruz, E E ^a  

^a CHARLES STURT UNIVERSITY   (Australia)

Author keywords

Antisense; c myc; Chemotherapy; Cisplatin

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CISPLATIN; MESSENGER RNA; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GRAFT; CANCER INHIBITION; CONTROLLED STUDY; DRUG RESISTANCE; GENE AMPLIFICATION; GENE REPRESSION; GENE TARGETING; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; RAT; TUMOR; TUMOR CELL;

EID: 0030049639     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.105     Document Type: Article

References (52)

1. ANDREWS PA AND HOWELL SB. (1990). Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells, 2, 35-43.
2. BIRO S, FU Y, YU Z AND EPSTEIN SE. (1993). Inhibitory effect of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration. Proc. Natl Acad. Sci. USA, 90, 654-658.
3. BURTON MA, JONES C, TROTTER JM, GRAY BN AND CODDE JP. (1990). Efficacy of ion-exchange resins for anti-tumour drug delivery. Regional Cancer Treat., 3, 36-39.
4. CHRISTEN RD, JEKUNEN AP, JONES JA, THIEBAUT F, SHALINSKY DR AND HOWELL SB. (1993). In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules. J. Clin. Invest., 92, 431-440.
5. CHOUGULE PB, SUK S, CHU Q, LEONE L, NIGRI PT, McRAE R, LEKAS M, BARONE A, BHAT D AND BELLINO J. (1994). Cisplatin as a sensitizer in the treatment of advanced head and neck cancers. Cancer, 74, 1927-1932.
6. EICHHOLTZ-WIRTH H, REIDEL G AND HEITEL B. (1993). Radiation-induced transient cisplatin resistance in murine fibrosarcoma cells associated with elevated metallothionein content. Br. J. Cancer, 67, 1001-1006.
7. 1 phase Chinese hamster V79-379A cells are inherently more sensitive to platinum bound to their DNA than mid S phase or asynchronous treated cells. Biochem. Pharmacol., 28, 1575-1580.
8. FUNATO T, YOSHIDA E, JIAO L, TONE T, KASHANI-SABET M AND SCANLON KJ. (1992). The utility of an anti-fos ribozyme in reversing cisplatin resistance in human carcinomas. Adv. Enzyme Regul., 32, 195-209.
9. GATELY DP AND HOWELL SB. (1993). Cellular accumulation of the anticancer agent cisplatin: a review. Br. J. Cancer, 66, 1171-1176.
10. GODWIN AK, MEISTER A, O'DWYER PJ, HUANG CS, HAMILTON TC AND ANDERSON ME. (1992). High resistance to cisplatin in human ovarian cancer cell lines is associated with a marked increase of gluthathione synthesis. Proc. Natl Acad. Sci. (USA)., 89, 3070-3074.
11. HANSON KD, SHICHIRI M, FOLLANSBEE MR AND SEDIVY JM. (1994). Effects of c-myc expression on cell cycle. Mol. Cell. Biol., 14, 5748-5755.
12. HAY N, TAKIMOTO M AND BISHOP JM. (1989). A Fos protein is present in a complex that binds a negative regulator of MYC. Genes Dev., 3, 293-303.
13. HAYASHI K, MAKINO R, KAWAMURA H, ARISAWA A AND YONEDA K. (1987). Characterisation of rat c-myc and adjacent regions. Nucleic Acids Res., 35, 6419-6436.
14. 1. Nature, 328, 445-449.
15. HERMEKING H AND EICK D. (1994). Mediation of c-myc induced apoptosis by p53. Science, 265, 2091-2093.
16. HOWELL DC. (1982). Statistical Methods for Psychology, Duxbury Press: Boston.
17. ISONISHI S, HOM DK, THIEBAUT FB, MANN SC, ANDREWS PA, BASU A, LAZO JS, EASTMAN A AND HOWELL SB. (1991). Expression of the c-Ha-ras oncogene in mouse NIH3T3 cells induces resistance to cisplatin. Cancer Res., 51, 5903-5909.
18. IVERSEN P. (1991). In vivo studies with phosphorothioate oligonucleotide: pharmacokinetics prologue. Anti-Cancer Drug Design, 6, 531-538.
19. KASAHARA K, EUJIWARA Y, NISHIO K, OHMORI T, SUGIMOTO Y, KOMIYA K, MATSUDA J AND SAIJO N. (1991). Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res., 51, 3237-3240.
20. KASHANI-SABET M, LU Y, LEONG L, HAEDICKE K AND SCANLON KJ. (1990). Differential oncogene amplification in tumour cells from a patient treated with cisplatin and 5-FU. Eur. J. Cancer, 26, 383-390.
21. KATO GJ, LEE WM, CHEN LL AND DANG CV. (1992). Max: functional domains and interaction with c-Myc. Genes Dev., 6, 81-92.
22. KELLAND LR, MISTRY P, ABEL G, LOH SY, O'NEILL CF, MURRER BA AND HARRAP KR. (1992). Mechanism-related circumvention of acquired cis-dichlorodiammineplatinum (II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/ amine platinum (IV) dicarboxylates. Cancer Res., 52, 3857-3864.
23. KOTAKE T, SAIKI S, KINOUCHI T, SHIKU H AND NAKAYAMA E. (1990). Detection of myc in urinary bladder cancer. Jpn. J. Cancer Res., 81, 1198-1201.
24. LOTEM J AND SACHS L. (1993). Regulation by bcl-2, c-myc and p53 of susceptibility of induction to apoptosis by heat shock and cancer chemotherapy compounds in differentiation competent and defective myeloid leukaemic cells. Cell Growth Differ., 4, 41-47.
25. MARAZZI L, PARODI MT, DiMARTINO D, FERRARI S AND TONINI GP. (1991). Coordinate change of c-myc, transferrin receptor and H3 gene expression precedes induction of haemoglobin-producing cells of the leukaemia K562 cell line treated with cis-diamminedichloroplatinum II. Anti-Cancer Res., 11, 947-952.
26. MARKMAN M. (1993). Current status of intraperitoneal therapy for ovarian cancer. Curr. Opin. Obstet. Gynecol., 5, 99-104.
27. MIZUTANI Y, FUKUMOTO M. BONAVIDA B AND YOSHIDA O. (1994). Enhancement of sensitivity of urinary bladder tumour cells to cisplatin by c-myc antisense oligonucleotide. Cancer, 74, 2546-2554.
28. NAKATA B, BARTON RM, ROBBINS KT, HOWELL SB AND LOS G. (1994). Association between hsp60 mRNA levels and cisplatin resistance in human head and neck cancer cell lines. Int. J. Oncol., 5, 1425-1432.
29. NAPOLI S, BURTON MA, MARTINS IJ, CHEN Y, CODDE JP AND GRAY BN. (1992). Dose response and toxicity of doxorubicin microsphere in a rat tumour model. Anti-Cancer Drugs, 3, 47-53.
30. NIIMI S, NAGAKAWA K, YOKOTA J, TSUNOKAWA Y, NISHIO K, TERASHIMA Y, SHIBUYA M, TERADA M AND SAIJO N. (1991). Resistance to drugs in NIH3T3 cells transfected with c-myc and c-Ha-ras genes. Br. J. Cancer, 63, 237-241.
31. OGUNBIYI OA, SCHOLEFIELD JH, ROGERS K, SHARP F, SMITH JH AND POLACARZ SV. (1993). C-myc expression in anal squamous neoplasia. J. Clin. Pathol., 46, 23-37.
32. OSMAK M. (1993). Multifactorial molecular mechanisms are involved in resistance of pre-irradiated human cervix carcinoma cells to cis-dichlorodiammineplatinum (II) and vincristine. Neoplasma, 40, 97-101.
33. PARIA BC, DEY SK AND ANDREWS GK. (1992). Antisense c-myc effects on pre-implantation mouse embryo development. Proc. Natl Acad. Sci. USA, 89, 10051-10055.
34. RUBIN E, KHARBANDA S, GUNJI H, WEICHSELBAUM R AND KUFE D. (1992). cis-dichloroplatinum (II) induces c-jun expression in human myeloid leukemia cells: potential involvement of a protein kinase C-dependent signaling pathway. Cancer Res., 52, 878-882.
35. SAMBROOK J, FRITSH EF AND MANIATIS T. (1989). Molecular Cloning: A Laboratory Manual, 2nd edn. Cold Spring Harbor Press: Cold Spring Harbor, NY.
36. SCANLON KJ AND KASHANI-SABET M. (1988). Elevated expression of dTMP synthase cycle genes in cisplatin resistant A2780 cells. Proc. Natl Acad. Sci. USA., 85, 650-653.
37. SHAW P, BOVEY R, TARDY S, SAHLI R, SORDAT B AND COSTA J. (1992). Induction of apoptosis by wild type p53 in a human colon tumour derived cell line. Proc. Natl Acad. Sci. USA., 89, 4495-4499.
38. 1 transition in non-transformed cells. Cell Growth Differ., 4, 93-104.
39. SKLAR MD AND PROCHOWNIK EV. (1991). Modulation of cis-platinum resistance in friend erythroleukemia cells by c-myc. Cancer Res., 51, 2118-2123.
40. SMITH DR, MYINT T AND GOH HS. (1993). Over-expression of c-myc in colorectal carcinoma. Br. J. Cancer, 68, 407-413.
41. SNEDECOR GW AND COCHRAN WG. (1967). Statistical Methods. 6th edn. Iowa State University Press: Ames, Iowa.
42. SPANDIDOS DA, ZOUMPOURLIS V AND LANG JC. (1991). Cisplatin responsive sequences in the human c-myc promoter. Anticancer Res., 11, 1339-1342.
43. SPENCER CA AND GROUDINE M. (1991). Control of c-myc regulation. Adv. Cancer Res., 56, 1-48.
44. STEIN CA AND CHENG YC. (1993). Antisense oligonucleotides as therapeutic agents is the bullet really magical? Science, 261, 1004-1011.
45. TASHIRO H, MIYAZAKI K, OKAMURA H. IWAI A AND FUKUMOTO M. (1992). C-myc over-expression in primary ovarian tumours. Int. J. Cancer, 50, 828-833.
46. TAVERNA P, HANSON J, SCANLON KJ AND HILL BT. (1994). Gene expression in X-irradiated human tumour cell lines expressing cisplatin resistance and altered DNA repair capacity. Carcinogenesis, 15, 2053-2056.
47. TOFFOLI G, VIEL A, TUMIOTTO L, BISCONTIN G, ROSSI C AND BOIOCCHI M. (1991). Pleiotropic resistant phenotype is a multifactorial phenomenon in human colon carcinoma cell lines. Br. J. Cancer, 63, 51-56.
48. TWENTYMAN PR, WRIGHT KA AND RHODES T. (1991). Radiation response of human lung cancer cells with inherent and acquired resistance to cisplatin. Int. J. Radiat. Oncol. Biol. Phys., 20, 217-220.
49. VOLM M, DRINGS P, WODRICH W AND VAN KAICK G. (1993). Expression of oncoproteins in primary human non-small cell lung cancer and incidence of metastasis. J. Clin. Exp. Met., 11, 325-329.
50. WATSON PH, SAFNECK JR, LE K, DUBIK D AND SHIU RP. (1993). Relationship of c-myc amplification to progression of breast cancer from in situ to invasive tumor and lymph node metastasis. J. Natl Cancer Inst., 85, 902-907.
51. YAGODA A AND PETRYLAK D. (1993). Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer, 71, 1098-1109.
52. YANG Y-W AND YANG MC. (1995). Effects of c-myc antisense transcripts on differentiation of K562 cells. Int. J. Oncol., 6, 419-424.